FigureAsia
Nomination Awards Winner

Healthcare

Thirty-five Asian and Asian-diaspora clinicians, scientists, bioengineers and builders whose completed 2025–26 work is already changing the terms of care.

Portrait of Aengus Tran Featured honouree Aengus Tran Healthcare · Sydney, Australia

Purpose and scope

Responsibility before recognition

Healthcare rarely rewards youth with a clean stage. Its most serious work is done inside long apprenticeships, regulated systems, crowded laboratories and clinics where every claim carries a human cost. That is precisely why this edition exists. FigureAsia set out to identify the young people who have already earned responsibility before the age of 35 — not because they are promising in the abstract, but because their work has begun to change what can be measured, manufactured, delivered, understood or reached.

Asia is not treated here as a single market or a visual shorthand. It is a vast, internally diverse geography of health systems, research traditions, capital constraints, disease burdens and diasporas. The editorial universe extends from East, Southeast, South and Central Asia to West Asia and the Middle East, and to people of Asian heritage building consequential work elsewhere. The list does not ask honourees to perform an identity. It asks whether their connection to Asia is real, documentable and relevant to the story of their work.

This is not a celebration of novelty without consequence. A prototype is not a treatment. A designation is not an approval. A company claim is not an audited outcome. A large model is not automatically a useful one. FigureAsia has therefore ranked evidence before applause and individual agency before institutional halo. Some honourees have reached patients or regulated pathways; others have produced preclinical or foundational work whose importance lies in opening a credible new route. Each profile states that maturity plainly.

The result is a portrait of healthcare as it is actually being rebuilt: by clinicians, bioengineers, computational scientists, public-health organizers, founders, materials researchers and systems operators. Their work differs in maturity and scale. What unites them is a record, inside the assessment window, strong enough to withstand questions after the ceremony is over.

Category definition

Work that acts directly on health

Healthcare is defined here through direct contribution to clinical care, medical research, biotechnology, digital health, medical devices, pharmaceuticals, public health or healthcare systems. General advocacy, celebrity, donation and indirect social impact are not sufficient on their own.

Selection priorities

Completed evidence over projected promise

The edition privileges completed work, individual agency and evidence proportionate to the claim. Regulatory, clinical, patient, revenue and attribution claims receive the closest scrutiny; an announced project or successful employer never substitutes for a person's own record.

FigureAsia methodology

How the field was assessed

The ranking was built independently by FigureAsia from a cross-border research field spanning Asia, West Asia and the Asian diaspora. Eligibility, direct healthcare contribution, completed work and individual responsibility were tested before scoring.

Assessment process

From the eligible field to the final cohort

The principal assessment window ran from 1 January 2025 through 17 July 2026. Earlier achievements were used only to establish context, continuity or agency; they did not carry the score. Announcements of future work, unsigned intentions, planned trials and aspirational market sizes were excluded from impact calculations.

Research proceeded claim by claim. Material statements were tested against primary or authoritative records wherever possible: peer-reviewed papers and author-contribution statements, regulator databases, trial records, grant notices, institutional appointments and official operating disclosures. A consequential claim normally required one primary or authoritative record plus an independent corroborator, or two independent records. When only organization-reported data existed, the claim could remain only with explicit attribution and a lower evidence score.

Every eligible finalist was scored on eleven dimensions. Seven universal dimensions account for 75 points; four healthcare-specific dimensions account for 25. Reviewers used a 0–5 scale in half-point increments, multiplied by the published weights. The numerical result disciplined comparison across very different forms of contribution. It did not replace editorial judgment. Ties were resolved by evidence quality, completed impact inside the window, individual agency and the maturity of the cited pathway.

The final order was reviewed for geographic breadth and disciplinary range only after scoring. Geography was never a quota capable of rescuing a weak file. The purpose of breadth was to prevent a narrow research network from defining “Asia,” not to lower the threshold. The published 35 all clear the same evidence and quality bar.

01 20%

Substantive 2025–2026 contribution

Scale, consequence and completeness of the work delivered inside the assessment window.

02 15%

Verified impact

Strength and independence of quantitative evidence, with patient, clinical, scientific or system outcomes preferred over publicity.

03 10%

Originality and distinction

Degree to which the work creates a new capability, evidence base, model of care or line of inquiry.

04 10%

Field and industry influence

Demonstrable effect on practice, research agendas, regulation, adoption or the work of other teams.

05 10%

Individual agency

Evidence that the honouree personally led, conceived, built or carried accountable responsibility for the cited work.

06 5%

Durability and trajectory

Likelihood that the contribution will compound beyond a single announcement or isolated result.

07 5%

Asian significance and global relevance

Strength of the honouree's Asian connection and the work's relevance across Asian and international health systems.

08 7%

Clinical and scientific validity

Quality of study design, external validation, regulatory evidence and precision of causal or clinical claims.

09 7%

Safety, quality and responsible governance

Attention to safety, bias, quality systems, data stewardship and accurate regulatory representation.

10 6%

Translation and care-pathway fit

Evidence that the work can move from laboratory or prototype into a usable clinical, operational or public-health pathway.

11 5%

Access, equity and resource stewardship

Potential or demonstrated contribution to affordability, reach, inclusion, capacity or responsible use of scarce resources.

Eligibility

The line every honouree had to clear

Every honouree had to remain under 35 on 31 December 2025. Where the reliable public record establishes only a year or a narrow age range, FigureAsia publishes an approximate age rather than presenting a guessed birthday as fact.

A material Asian or Asian-diaspora connection and a direct, substantial healthcare contribution were mandatory. The decisive achievement had to be complete by the evidence cut-off and attributable to the individual.

Year-based age rule

Eligibility uses a reliable birth year, dated age statement or age-bounded cohort record. Approximate ages are labelled conservatively; exact birthdays are not displayed.

Completed-work rule

Only completed 2025–26 work is scored. Announcements, projected potential, titles and publicity receive no achievement credit.

Healthcare-category rule

The contribution must act directly through care, research, biotechnology, digital health, devices, pharmaceuticals, public health or health systems.

Individual-attribution rule

Organisation and team outcomes are credited only to the extent supported by the honouree's documented role.

Evidence threshold

Every profile retains at least two reliable core records; decisive claims require authoritative support and high-risk claims require independent corroboration.

Evidence-boundary rule

Regulatory status, clinical maturity and outcome limitations remain explicit. Feasibility, preclinical and observational evidence is never rewritten as proven patient benefit.

One framework

All 35 honourees are assessed on the same eleven dimensions and published weights.

Corrections principle

Material errors are corrected promptly and judgments revisited when reliable new evidence changes the record.

Publication standards

Editorial, legal and rights notices

This edition is an independent editorial assessment, not a credential, endorsement or substitute for professional judgment.

01

Editorial independence

FigureAsia conceived, researched, scored, ordered and wrote this edition as an independent editorial work. Placement cannot be purchased. No honouree, employer, investor, nominator, sponsor, publicist or external ranking organization was given a right of approval over inclusion, rank, wording or exclusion. Commercial prominence, fundraising and social reach were never treated as substitutes for evidence.

02

Evidence and corrections

Facts are stated only to the level supported at the evidence cut-off. FigureAsia will correct material errors and revisit a profile when reliable new records require it.

03

Clinical and regulatory limits

This publication is an editorial work for general information and public-interest discussion. It is not medical advice, a clinical guideline, a scientific consensus statement, legal advice, investment advice, due diligence, certification, accreditation or an instruction to use any product, service, test, medicine, device or care pathway.

Inclusion does not constitute an endorsement of an honouree, employer, affiliated entity, security, product, research conclusion or commercial claim. Rank does not measure clinical competence and must not be used to select a clinician or make a treatment decision. Readers should consult appropriately licensed professionals and the relevant regulator in their jurisdiction.

Regulatory descriptions are jurisdiction-specific and time-sensitive. “Cleared,” “authorized,” “registered,” “listed,” “designated,” “accepted into a programme” and “approved” have distinct meanings and are not interchangeable. Research described as in vitro, ex vivo, animal, retrospective, observational, feasibility-stage, preprint or pilot should not be read as proof of safety or benefit in routine patient care.

04

Names, marks and affiliation

Names of institutions, companies, journals, regulators, products and trademarks appear only for identification and factual context. All marks remain the property of their respective owners. Their appearance does not imply sponsorship, affiliation or approval of FigureAsia or this edition.

05

Time-sensitive record

The record is a snapshot as of 17 July 2026. Roles, evidence, regulatory status, company metrics and affiliations may change. FigureAsia has taken reasonable editorial care but does not warrant that every public record is complete, current or free from error. FigureAsia may correct, annotate, revise or withdraw a profile when credible new evidence emerges. Corrections should identify the precise statement at issue and provide documentary support.

06

Editorial judgment

To the fullest extent permitted by law, FigureAsia and its contributors disclaim liability arising from reliance on this publication. Methodology, scoring, selection, ordering, headlines and editorial characterization are protected exercises of editorial judgment. No person acquires a right to inclusion, continued inclusion, a particular rank or advance review.

07

Originality

The cohort, ordering, scoring framework and editorial text are original FigureAsia work. Inclusion cannot be purchased and no outside party controls rank or wording.

08

Portraits and rights

Portraits are used for identification in an editorial context. Each published image has a documented source and credit; where a suitable portrait cannot be used responsibly, FigureAsia uses its own house artwork.

09

Copyright

© 2026 FigureAsia. All rights reserved.